One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Hip Fractures

In brief

The goal of this clinical trial is to learn whether giving one dose or two doses of tranexamic acid can safely lower blood loss in older adults having surgery for certain hip fractures. The study includes adults aged 65 years or older who need surgery for pertrochanteric or subtrochanteric hip fractures. The main questions the study aims to answer are: * Does giving two doses of tranexamic acid lower the need for blood transfusions compared to one dose? * Does tranexamic acid help keep hemoglobin levels higher after surgery? * Is tranexamic acid safe in this group of participants? Researchers will compare participants who receive one dose of tranexamic acid with those who receive two doses to see which approach works better and is safe. Participants will: * Receive either one dose of tranexamic acid before surgery or two doses, one before and one after surgery * Have standard surgery to fix their hip fracture within 48 hours of hospital admission * Be monitored during their hospital stay for blood loss, transfusions, and medical problems * Be followed for up to 90 days after surgery to check for safety A total of 120 participants will take part in this study, which is being conducted at the University Clinic "St. Naum Ohridski" in Skopje, North Macedonia.

Key facts

Study ID

NCT07432737

Run by

University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje

People needed

120

Starts

2026-02-17

Expected to finish

2027-09-01

Last updated by the study team

2026-02-27

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained
• Patients aged 65 years or older
• Patients with pertrochanteric femoral fracture (AO/OTA classification: 31A1.2, 31A1.3, 31A2, 31A3) or subtrochanteric femoral fracture (AO/OTA classification: 32; fractures from the level of the lesser trochanter to 5 cm distally)
• Surgical treatment performed within 48 hours of hospital admission

You may not qualify if…

• Age younger than 65 years
• Known allergy or hypersensitivity to tranexamic acid
• Active thromboembolic event (deep vein thrombosis, arterial thrombosis, pulmonary embolism) or history of vascular event within the past year (myocardial infarction, coronary or peripheral vascular stenting, thromboembolism, stroke)
• Impaired renal function defined as serum creatinine >120 µmol/L in the last preoperative laboratory test
• History of malignant disease
• History of seizure disorder or chronic anticonvulsant therapy
• Polytrauma or multiple trauma
• More than one fracture
• Previous fracture of the same hip
• Preoperative hemoglobin level <8 g/dL (last laboratory test before surgery)
• Thrombocytopenia or other coagulation disorders
• Treatment with vitamin K antagonists with INR >1.5
• Treatment with low-molecular-weight heparins without appropriate preoperative discontinuation according to clinical protocol (usually ≥24 hours for prophylactic doses and ≥24-36 hours for therapeutic doses)
• Treatment with direct oral anticoagulants without appropriate preoperative discontinuation (usually 24-48 hours, depending on renal function and bleeding risk)
• Treatment with P2Y12 inhibitors (e.g., ticagrelor, clopidogrel, prasugrel) when, according to anesthesiologist assessment, surgery cannot be safely performed within 48 hours

Where it is running

• University Clinic PHI University Clinic for Surgical Diseases, St. Naum Ohridski — Skopje, North Macedonia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.